MedTrace Logo

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

NCT00422019 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2015-04-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.

Conditions

  • Advanced Renal Cell Carcinoma

Interventions

DRUG

AMG 102 at 10 mg/kg

AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks

DRUG

AMG 102 at 20 mg/kg

AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-03-31
Completion
2009-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00422019 on ClinicalTrials.gov